Completion of retail component of Entitlement Offer
Filed with ASX · · 2 pages · English
On 21 February 2022, Chimeric Therapeutics Limited (ASX:CHM) (Chimeric orCompany) announced the details of an accelerated non-renounceable entitlement offer (Entitlement Offer) to raise approximately $18 million (before costs of the offer). Chimeric announced the successful completion of the Institutional component of the Entitlement Offer on 23 February 2022, which raised approximately $7.4 milli
Chimeric Therapeutics Limited on 6ix
Story so far
Earlier from Chimeric Therapeutics
- Security Class Suspension from Quotation CHMO
- Final Results in Phase 1 Trial of CORE NK Platform
- Chimeric partners with Be the Match BioTherapies
- Successful completion of Institutional Entitlement Offer
- Entitlement Offer to raise approximately $18.1 million
Later from Chimeric Therapeutics
- CDH17 CAR t preclinical data featured in Nature Cancer
- Security Class Reinstatement to Quotation CHMO
- Strategic manufacturing partnership with WuXi ATU
- A$30 million Equity Placement Agreement with L1 Capital
- Licenses viral vector technology from Penn for CDH17
Follow Chimeric Therapeutics into a list and get an email when it puts out news.
Follow Chimeric Therapeutics